Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.53. Xtant Medical shares last traded at $0.52, with a volume of 94,800 shares trading hands.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the company a “buy” rating in a research note on Friday, October 18th.

Xtant Medical Stock Down 1.3 %

The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.01 and a current ratio of 2.44. The firm has a market capitalization of $67.60 million, a P/E ratio of -25.94 and a beta of 0.39.

Hedge Funds Weigh In On Xtant Medical

Several large investors have recently made changes to their positions in XTNT. Evernest Financial Advisors LLC acquired a new stake in shares of Xtant Medical in the third quarter valued at $27,000. Juniper Investment Company LLC acquired a new position in Xtant Medical during the 1st quarter worth $408,000. Finally, Vanguard Group Inc. grew its stake in Xtant Medical by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock worth $1,812,000 after purchasing an additional 48,319 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.